Parabilis Medicines (PBLS) news
Recent news
Alphabet Inc reports share stake of 4.92 mln common shares in Parabilis Medicines
Alphabet Inc. has reported a shareholding of 4.92 million common shares in Parabilis Medicines, according to recent filings. This stake represents a notable investment in the clinical-stage biopharmaceutical company, which recently completed a record-breaking $670 million initial public offering .…
AInvest Wire · Aug 7, 2026Parablis Medicines, Inc: BofA Global Research initiates coverage with buy rating and price objective $45.00
Bank of America Global Research has initiated coverage on Parabilis Medicines, Inc. (PBLS) with a "Buy" rating and a price objective of $45.00 per share. The move reflects the firm’s confidence in the company’s growth potential and strategic positioning within the biopharmaceutical sector. BofA’s…
AInvest Wire · Jul 6, 2026Kardigan upsized IPO prices at $16/shr
Kardigan, a cardiovascular-focused biotechnology company, has priced its upsized initial public offering (IPO) at $16 per share, raising a total of $372.8 million . The company initially filed to offer 23.3 million shares at a range of $14 to $16 per share. With the final price set at the top of…
AInvest Wire · Jun 18, 2026Parabulis to sell 4.17M shares to Regeneron Pharma at $18 per share
Parabilis Medicines has agreed to issue 4.17 million shares to Regeneron Pharmaceuticals at a price of $18 per share as part of a broader strategic collaboration between the two companies. This equity commitment is a component of the $75 million investment by Regeneron in Parabilis’ next equity…
AInvest Wire · Jun 10, 2026Parabulis Medicines raises IPO offering to 33.5M shares
Parabilis Medicines, a clinical-stage biotechnology company, has filed for an initial public offering (IPO) and is offering 33.5 million shares to the public. The company, formerly known as FogPharma, has raised over $800 million in private funding since its founding in 2015 and has spent nearly…
AInvest Wire · Jun 10, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.